We are incredibly proud of our team’s involvement with olaparib, which continues to impact the lives of many cancer patients. Our CEO Niall Martin and CSO Graeme Smith were instrumental in the discovery of olaparib, and other promising inhibitors of key proteins involved in the DNA damage response (DDR) pathways at KuDOS Pharmaceuticals, a biotech company started by Professor @Sir Stephen (Steve) Jackson in 1997 and later acquired by AstraZeneca. Olaparib was developed based on the idea that inhibiting DNA repair enzymes could help kill cancer cells. During its remarkable development journey, a key discovery was that this PARP inhibitor could target a particular weakness in cancer cells driven by mutations in specific genes. Today, tens of thousands of patients with cancer have been treated with olaparib based on early basic research discoveries. Reflecting on these milestones fuels our inspiration and commitment to the ongoing innovation and work we are currently doing at Artios. We continue using the knowledge we have gained from past successes to pioneer the next generation of DDR drugs, pushing the boundaries of cancer treatment and providing new solutions for patients in need. To learn more about what we do, visit our website at: https://www.artios.com/ #ArtiosPharma #CancerTreatment #ChangingTheStoryofCancer #Cambridge
💊 Cambridge research has led to a life-saving cancer drug. In 1999, Professor Sir Stephen (Steve) Jackson set up a team of scientists that created olaparib, a new class of cancer drug, which has now been used to treat over 140,000 patients globally and changed the outlook for people with breast, ovarian, prostate and pancreatic cancers. Find out how we're #ChangingTheStoryOfCancer 👉 https://lnkd.in/exCesBsY #CambridgeUniversity #UniversityOfCambridge #Cambridge #Cancer #CancerDiagnosis